943320-63-6

Basic information

• Product Name: [(R)-1-(4-amino-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-dimethyl-amine
• Synonyms: [(R)-1-(4-amino-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-dimethyl-amine
• CAS NO: 943320-63-6
• Molecular Weight: 287.328
• Mol File: 943320-63-6.mol

Chemical Properties

• CAS DataBase Reference: [(R)-1-(4-amino-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-dimethyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: [(R)-1-(4-amino-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-dimethyl-amine(943320-63-6)
• EPA Substance Registry System: [(R)-1-(4-amino-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-dimethyl-amine(943320-63-6)

Safety Data

• Hazardous Substances Data: 943320-63-6(Hazardous Substances Data)

Upstream product

• 943320-62-5 dimethyl-[(R)-1-(4-nitro-2-trifluoromethyl-benzyl)-pyrrolidin-3-yl]-amine 
• 89976-12-5 1-methyl-4-nitro-2-(trifluoromethyl) benzene 
• 694499-22-4 1-(bromomethyl)-4-nitro-2-(trifluoromethyl) benzene 
• 1408000-40-7 tert-butyl N-[4-(bromomethyl)-3-(trifluoromethyl)phenyl]carbamate 
• 1408000-39-4 tert-butyl N-[4-methyl-3-(trifluoromethyl)phenyl]carbamate 
• 65934-74-9 3-(trifluoromethyl)-4-methylaniline 

Downstream Products

• 1408000-43-0 (R)-3-azido-N-(4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide 
• 1408000-03-2 C₃₀H₃₀F₃N₉O 

Relevant articles and documents

ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES

The present invention discloses compounds according to Formula (I) wherein R1, R2, R3, L1, L2, and L3 are as defined herein. The present invention relates to compounds inhibiting discoidin domain receptors (DDRs), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, inflammatory diseases, respiratory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering a compound of the invention.

NOVEL IMIDAZOPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER

The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative acco

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

The present invention relates to substituted pyrimidinyl- and pyridinylpyrrolopyridinone compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions containing these compounds.

METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES

The invention discloses methods and compositions for treating or preventing RAF kinase mediated diseases or conditions by administering a compound of Formula 1: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.

Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl) benzamide derivatives as potent pan Bcr-Abl inhibitors including the threonine315←isoleucine315 mutant

A series of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives were designed and synthesized as new Bcr-Abl inhibitors by using combinational strategies of bioisosteric replacement, scaffold hopping, and conformational constraint. The compounds displayed significant inhibition against a broad spectrum of Bcr-Abl mutants including the gatekeeper T315I and p-loop mutations, which are associated with disease progression in CML. The most potent compounds 6q and 6qo strongly inhibited the kinase activities of Bcr-AblWT and Bcr-AblT315I with IC50 values of 0.60, 0.36 and 1.12, 0.98 nM, respectively. They also potently suppressed the proliferation of K562, KU812 human CML cells, and a panel of murine Ba/F3 cells ectopically expressing either Bcr-AblWT or any of a panel of other Bcr-Abl mutants that have been shown to contribute to clinical acquired resistance, including Bcr-AblT315I, with IC50 values in low nanomolar ranges. These compounds may serve as lead compounds for further development of new Bcr-Abl inhibitors capable of overcoming clinical acquired resistance against imatinib.

BICYCLIC HETEROARYL COMPOUNDS

This invention relates to compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.